JP2023533030A5 - - Google Patents

Info

Publication number
JP2023533030A5
JP2023533030A5 JP2023501079A JP2023501079A JP2023533030A5 JP 2023533030 A5 JP2023533030 A5 JP 2023533030A5 JP 2023501079 A JP2023501079 A JP 2023501079A JP 2023501079 A JP2023501079 A JP 2023501079A JP 2023533030 A5 JP2023533030 A5 JP 2023533030A5
Authority
JP
Japan
Prior art keywords
dose
patients weighing
less
antibody
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023501079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533030A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/040802 external-priority patent/WO2022011086A1/en
Publication of JP2023533030A publication Critical patent/JP2023533030A/ja
Publication of JP2023533030A5 publication Critical patent/JP2023533030A5/ja
Pending legal-status Critical Current

Links

JP2023501079A 2020-07-09 2021-07-08 小児患者において発作性夜間血色素尿症(pnh)を治療するための抗c5抗体の投薬量及び投与 Pending JP2023533030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063049768P 2020-07-09 2020-07-09
US63/049,768 2020-07-09
PCT/US2021/040802 WO2022011086A1 (en) 2020-07-09 2021-07-08 Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients

Publications (2)

Publication Number Publication Date
JP2023533030A JP2023533030A (ja) 2023-08-01
JP2023533030A5 true JP2023533030A5 (cg-RX-API-DMAC7.html) 2025-10-03

Family

ID=77127113

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023501079A Pending JP2023533030A (ja) 2020-07-09 2021-07-08 小児患者において発作性夜間血色素尿症(pnh)を治療するための抗c5抗体の投薬量及び投与

Country Status (4)

Country Link
US (1) US20230235035A1 (cg-RX-API-DMAC7.html)
EP (2) EP4295905A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023533030A (cg-RX-API-DMAC7.html)
WO (1) WO2022011086A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3024618A1 (en) 2016-05-27 2017-11-30 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CN116194478A (zh) 2020-06-24 2023-05-30 阿雷克森制药公司 皮下(sc)施用抗c5抗体治疗补体相关病症
WO2024227120A1 (en) * 2023-04-27 2024-10-31 Alexion Pharmaceuticals, Inc. Systems and methods for monitoring quality of life (qol) features in pnh patients treated with complement pathway inhibitors
EP4705337A1 (en) * 2023-05-02 2026-03-11 Alexion Pharmaceuticals, Inc. Pediatric dosage and administration of anti-c5 antibodies for treatment of complement disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
PY09026846A (es) 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
NZ711451A (en) 2014-03-07 2016-05-27 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
EA201791366A1 (ru) * 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
IL263481B2 (en) * 2016-06-14 2024-06-01 Regeneron Pharma Anti-c5 antibodies and uses thereof
EP3802593B1 (en) * 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients

Similar Documents

Publication Publication Date Title
JP2021525718A5 (cg-RX-API-DMAC7.html)
US12528859B2 (en) Single domain serum albumin binding protein
JP2022512632A5 (cg-RX-API-DMAC7.html)
JP7489978B2 (ja) 抗FcRn抗体を用いたグレーブス眼症の治療方法
JP2021501134A5 (cg-RX-API-DMAC7.html)
JP2021526534A5 (cg-RX-API-DMAC7.html)
JP2018511609A5 (cg-RX-API-DMAC7.html)
JP2023533682A5 (cg-RX-API-DMAC7.html)
JP2020536097A5 (cg-RX-API-DMAC7.html)
JP2020528894A5 (cg-RX-API-DMAC7.html)
WO2017064615A1 (en) Use of c5 inhibitors in transplant associated microangiopathy
EA014025B1 (ru) Композиции антитела против cd3
JP2020504110A5 (cg-RX-API-DMAC7.html)
WO2018109588A2 (en) Stable aqueous anti-c5 antibody composition
JP2023528441A5 (cg-RX-API-DMAC7.html)
RU2003126168A (ru) Терапевтические связывающие молекулы
JP2024540435A5 (cg-RX-API-DMAC7.html)
TW202417482A (zh) 治療補體介導疾病的方法
JP2023510854A5 (cg-RX-API-DMAC7.html)
JP2025515076A5 (cg-RX-API-DMAC7.html)
JP2023539047A5 (cg-RX-API-DMAC7.html)
JP2018533588A (ja) 治療パラダイム
JP2023504209A5 (cg-RX-API-DMAC7.html)
KR20230009431A (ko) 발작성 야간 혈색소뇨증의 치료를 위한 보체 인자 d 저해제를 단독으로 또는 항-c5 항체와 조합한 용도
JP2022520572A5 (cg-RX-API-DMAC7.html)